Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:15:02 23/05/2024 BST			5-day change	1st Jan Change
0.0013 ^USD	-7.14%		+18.18%	-85.06%

2023	Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	CI

Endonovo Therapeutics, Inc. Appoints Peter Novak to Scientific Advisory Board

July 15, 2019 at 01:30 pm

Endonovo Therapeutics, Inc. announced the appointment of Peter Novak, M.D., Ph.D., to its Scientific Advisory Board. Peter Novak, M.D., Ph.D., is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties.

Latest news about Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	12-29	CI
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	12/10/23	CI
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22/08/23	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	07/06/23	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	02/05/23	CI
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	25/04/23	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	16/04/23	CI
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan	23/03/23	CI
Endonovo Announces Distribution Agreement with Academy Medical	06/03/23	CI
Endonovo Partners with International Distributor for SofPulse Line	26/01/23	CI
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company	09/01/23	CI
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics.	08/01/23	CI
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion	30/11/22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11/22	CI
Endonovo Therapeutics, Inc. entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.	26/09/22	CI
Endonovo Therapeutics Releases Comparative Analysis Demonstrating	28/07/22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	19/05/22	CI
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products	25/04/22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	14/04/22	CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	13/04/22	CI
Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development	01/03/22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	19/11/21	CI

Chart Endonovo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.

Sector

Biotechnology & Medical Research

Calendar

16/06/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENDONOVO THERAPEUTICS, INC.	-85.06%	454K
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.43%	22.1B
GENMAB A/S	-9.00%	18.34B
WUXI APPTEC CO., LTD.	-41.70%	16.59B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs